leadf
logo-loader
viewMountain Valley MD Holdings Inc

Mountain Valley MD adds South African Variant to Bio Safety Level 4 lab study

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) Director of Life Scienced Mike Farber joined Steve Darling from Proactive with news the company has announced they are adding the South African Variant to their upcoming Bio Safety Level 4 lab study, which is analyzing viral clearance efficacy with the Company's Ivermectin technology.

Farber talks about why they thought this was an important step to take considering there is concern about the variant whether the vaccines are rendered less effective against the variant.

Quick facts: Mountain Valley MD Holdings Inc

Price: 1.34 CAD

CSE:MVMD
Market: CSE
Market Cap: $334.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Mountain Valley MD proceeding with program to get FDA approval for Novel...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock joined Steve Darling with Proactive to bring news the company has engaged the services of Camargo Pharmaceutical services to help navigate the waters of the FDA as they continue with their application for Novel Ivectosol. Hancock...

5 hours, 24 minutes ago

2 min read